Ubs Asset Management Americas Inc Amicus Therapeutics, Inc. Transaction History

Ubs Asset Management Americas Inc

$417 Billion
Q4 2024

A detailed history of Ubs Asset Management Americas Inc transactions in Amicus Therapeutics, Inc. stock. As of the latest transaction made, Ubs Asset Management Americas Inc holds 958,671 shares of FOLD stock, worth $6.44 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

958,671

Previous 486,769 96.95%

Holding current value

$6.44 Million

Previous $5.2 Million 73.72%

% of portfolio

0.0%

Previous 0.0%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	BUY	$9.36 - $12.01 $4.42 Million - $5.67 Million	471,902 Added 96.95%	958,671 $9.03 Million
Q3 2024 Nov 14, 2024	SELL	$9.55 - $12.09 $451,810 - $571,977	-47,310 Reduced 8.86%	486,769 $5.2 Million
Q2 2024 Aug 13, 2024	BUY	$9.04 - $11.75 $2.56 Million - $3.32 Million	282,846 Added 112.58%	534,079 $5.3 Million
Q1 2024 May 15, 2024	SELL	$11.43 - $14.24 $75,060 - $93,514	-6,567 Reduced 2.55%	251,233 $2.96 Million
Q4 2023 Feb 14, 2024	BUY	$9.97 - $14.52 $117,257 - $170,769	11,761 Added 4.78%	257,800 $3.66 Million
Q3 2023 Nov 13, 2023	SELL	$11.78 - $13.86 $298,776 - $351,531	-25,363 Reduced 9.35%	246,039 $2.99 Million
Q1 2023 May 15, 2023	BUY	$10.91 - $13.54 $237,085 - $294,237	21,731 Added 8.7%	271,402 $3.01 Million
Q4 2022 Feb 14, 2023	BUY	$9.89 - $12.7 $284,604 - $365,467	28,777 Added 13.03%	249,671 $3.05 Million
Q3 2022 Nov 14, 2022	SELL	$9.82 - $12.75 $496,744 - $644,958	-50,585 Reduced 18.63%	220,894 $2.31 Million
Q2 2022 Aug 12, 2022	BUY	$6.23 - $11.12 $15,282 - $27,277	2,453 Added 0.91%	271,479 $2.92 Million
Q1 2022 May 16, 2022	SELL	$7.89 - $12.48 $82,537 - $130,553	-10,461 Reduced 3.74%	269,026 $2.55 Million
Q4 2021 Feb 14, 2022	SELL	$9.82 - $12.44 $60,432 - $76,555	-6,154 Reduced 2.15%	279,487 $3.23 Million
Q3 2021 Nov 15, 2021	SELL	$8.74 - $11.84 $342,573 - $464,080	-39,196 Reduced 12.07%	285,641 $2.73 Million
Q2 2021 Aug 16, 2021	BUY	$8.71 - $10.72 $89,608 - $110,287	10,288 Added 3.27%	324,837 $3.13 Million
Q1 2021 May 14, 2021	BUY	$9.2 - $23.86 $243,404 - $631,264	26,457 Added 9.18%	314,549 $3.11 Million
Q4 2020 Mar 01, 2021	SELL	$13.47 - $24.89 $16.4 Million - $30.3 Million	-1,217,486 Reduced 80.87%	288,092 $6.65 Million
Q3 2020 Nov 13, 2020	BUY	$12.89 - $15.89 $15.7 Million - $19.3 Million	1,215,044 Added 418.21%	1,505,578 $21.3 Million
Q2 2020 Aug 14, 2020	SELL	$8.86 - $15.69 $35,980 - $63,717	-4,061 Reduced 1.38%	290,534 $4.38 Million
Q1 2020 May 15, 2020	BUY	$6.63 - $11.16 $121,236 - $204,071	18,286 Added 6.62%	294,595 $2.72 Million
Q4 2019 Feb 14, 2020	BUY	$7.48 - $10.75 $210,846 - $303,021	28,188 Added 11.36%	276,309 $2.69 Million
Q3 2019 Nov 14, 2019	BUY	$8.02 - $13.25 $321,882 - $531,788	40,135 Added 19.3%	248,121 $1.99 Million
Q2 2019 Aug 15, 2019	BUY	$10.96 - $14.4 $550,389 - $723,139	50,218 Added 31.83%	207,986 $0
Q1 2019 May 14, 2019	BUY	$10.04 - $13.92 $205,277 - $284,608	20,446 Added 14.89%	157,768 $0
Q4 2018 Feb 13, 2019	BUY	$8.38 - $13.44 $166,016 - $266,259	19,811 Added 16.86%	137,322 $1.32 Million
Q3 2018 Nov 14, 2018	SELL	$11.6 - $16.54 $15,474 - $22,064	-1,334 Reduced 1.12%	117,511 $0
Q2 2018 Aug 14, 2018	SELL	$13.13 - $17.09 $67,186 - $87,449	-5,117 Reduced 4.13%	118,845 $0
Q1 2018 May 14, 2018	BUY	$13.76 - $17.12 $261,673 - $325,571	19,017 Added 18.12%	123,962 $0
Q4 2017 Feb 09, 2018	BUY	$12.51 - $16.24 $510,320 - $662,478	40,793 Added 63.59%	104,945 $0
Q3 2017 Nov 13, 2017	BUY	$11.74 - $15.78 $753,144 - $1.01 Million	64,152	64,152 $0

Others Institutions Holding FOLD

# of Institutions

308

Shares Held

283M

Call Options Held

467K

Put Options Held

515K

View Full List

About AMICUS THERAPEUTICS, INC.

Ticker FOLD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 280,497,984
Market Cap $1.88B
Description
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant bas...

More about FOLD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Asset Management Americas Inc, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Asset Management Americas Inc with notifications on news.

Account

Ubs Asset Management Americas Inc Amicus Therapeutics, Inc. Transaction History